Bone health management of Australian breast cancer survivors receiving hormonal therapy.
Breast cancer survivors are at risk of bone loss due to hormonal treatment. We conducted a case note audit to investigate patterns of care and adherence to guidelines for initial management of risk of bone loss in 42 women receiving hormonal therapy. All those receiving aromatase inhibitors (n = 14) and 10 on tamoxifen had a bone density assessment. Eleven (26%) women had osteopenia and four (9.5%) osteoporosis. Management was variable and not always aligned with the guidelines.
Discipline of Nutrition and Dietetics, Flinders University, Adelaide, South Australia, Australia.
R
R
Roberts
Discipline of Nutrition and Dietetics, Flinders University, Adelaide, South Australia, Australia.
M
M
Miller
Urology Unit, SA Health, Repatriation General Hospital, Adelaide, South Australia, Australia.
M
M
O'Callaghan
Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders University and Flinders Medical Centre, Adelaide, South Australia, Australia.
B
B
Koczwara
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D019468:Disease Management; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D012189:Retrospective Studies; D017741:Survivors; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D013629:Tamoxifen
aromatase inhibitors; bone; breast cancer; osteoporosis